Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: A link between healthy and unhealthy obesity?

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 1957-1966

  Uribarri, Jaime ^a   Cai, Weijing ^a   Woodward, Mark ^b,c   Tripp, Elizabeth ^a   Goldberg, Laurie ^a   Pyzik, Renata ^a   Yee, Kalle ^a   Tansman, Laurie ^a   Chen, Xue ^a   Mani, Venkatesh ^a   Fayad, Zahi A ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; LACTOYLGLUTATHIONE LYASE; LEPTIN; METHYLGLYOXAL; PROTEIN AGER1; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; DIETARY INTAKE; FAT MASS; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METABOLITE; MIDDLE AGED; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRIENT UPTAKE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; BLOOD; COMPLICATION; RISK FACTOR;

SALVIA;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84929359452     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3925     Document Type: Article

References (39)

1. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27(10): 2444-2449.
2. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation. 2008;117(6):754-761.
3. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
4. Roberson LL, Aneni EC, Maziak W, et al. Beyond BMI: The "metabolically healthy obese" phenotype, its association with clinical/subclinical cardiovascular disease and all-cause mortality - a systematic review. BMC Public Health. 2014;14:14.
5. Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1(2):152-162.
6. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7(9):526-539.
7. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a populationbased 18 year follow-up study. Diabetologia. 2007;50(7):1409-1417.
8. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002;25(6):1055-1059.
9. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110(6):911-916.e912.
10. Birlouez-Aragon I, Saavedra G, Tessier FJ, et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr. 2010;91(5):1220-1226.
11. Finot PA. Historical perspective of the Maillard reaction in food science. Ann NY Acad Sci. 2005;1043:1-8.
12. Nguyen HT, van der Fels-Klerx HJ, van Boekel MAJS. N-epsilon- (carboxymethyl)lysine: a review on analytical methods, formation, and occurrence in processed food, and health impact. Food Rev Int. 2014;30(1):36-52.
13. Vlassara H, Cai W, Goodman S, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab. 2009;94(11):4483-4491.
14. Uribarri J, Cai W, Pyzik R, et al. Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids. 2014;46(2):301-309.
15. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol. 2009;5(7):367-373.
16. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA. 2004;101(32):11767-11772.
17. Mark AB, Poulsen MW, Andersen S, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care. 2014; 37(1):88-95.
18. Monden M, Koyama H, Otsuka Y, et al. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes. 2013;62(2):478-489.
19. Tahara N, Yamagishi S, Matsui T, et al. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther. 2012; 30(1):42-48.
20. Gaens KH, Goossens GH, Niessen PM, et al. Nε-(carboxymethyl) lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol. 2014; 34(6):1199-1208.
21. Uribarri J, Cai W, Ramdas M, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011; 34(7):1610-1616.
22. Song F, Hurtado del Pozo C, et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes. 2014; 63(6):1948-1965.
23. Sebekova K, Krivosikova Z, Gajdos M. Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic youngto-middle-aged medication-free subjects. Clin Chem Lab Med. 2014;52(1):139-149.
24. Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L. Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr. 2011;141(9):1726-1730.
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106(25): 3143-3421.
26. Bonekamp S, Ghosh P, Crawford S, et al. Quantitative comparison and evaluation of software packages for assessment of abdominal adipose tissue distribution by magnetic resonance imaging. Int J Obes (Lond). 2008;32(1):100-111.
27. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8(7):337-346.
28. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA. 2012;109(39):15888-15893.
29. de Kreutzenberg SV, Ceolotto G, Papparella I, et al. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes. 2010;59(4):1006-1015.
30. Poulsen MW, Bak MJ, Andersen JM, et al. Effect of dietary advanced glycation end products on postprandial appetite, inflammation, and endothelial activation in healthy overweight individuals. Eur J Nutr. 2014;53(2):661-672.
31. Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934-942.
32. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am. 2004;33(2):333-350.
33. Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009;29(5):1363-1374.
34. Takemura Y, Ouchi N, Shibata R, et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest. 2007;117(2):375-386.
35. Torreggiani M, Liu H, Wu J, et al. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009; 175(4):1722-1732.
36. Brouwers O, Niessen PM, Ferreira I, et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem. 2011;286(2):1374-1380.
37. Yoshizaki T, Schenk S, Imamura T, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;298(3):E419-E428.
38. Liu J, Hickson DA, Musani SK, et al. Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk factors in African Americans: the Jackson heart study. Obesity (Silver Spring). 2013; 21(3):644-651.
39. Scott RA, Fall T, Pasko D, et al. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independently of obesity. Diabetes 2014;63(12):4378-4387.